4.6 Review

C-reactive protein and cardiovascular risk in bipolar disorder patients: A systematic review

Journal

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pnpbp.2017.07.026

Keywords

Bipolar disorder; Cardiovascular disease; Cardiovascular risk factors; C-reactive protein; Inflammation; Metabolic syndrome; Review

Funding

  1. Canadian Institutes of Health Research Fellowship Award
  2. Deutsche Forschungsgemeinschaft (DFG) [BO 4229/1-1, BO 4229/2-1]

Ask authors/readers for more resources

Objectives: New research is revealing a strong association between inflammatory markers with bipolar disorder (BD), potentially due to the high prevalence of cardiovascular disease and cardiovascular risk factors in BD. We aimed to synthesize the literature examining the association between the clinically most relevant inflammatory marker, C-reactive protein (CRP) and cardiovascular disease and cardiovascular risk factors in patients with BD. Methods: MEDLINE, Embase and PsychInfo were systematically searched for all relevant English language articles published prior to April 2017. Articles were included if they examined the association between CRP and cardiovascular risk factors/disease in BD. Results: Fifteen relevant articles were retrieved. Studies were mostly cross-sectional and heterogeneous in the cardiovascular risk factors investigated. Overall, elevated CRP was associated with increased risk of metabolic syndrome, elevated body mass index, higher waist circumference, and obesity. CRP was inconsistently associated with elevated fasting glucose, insulin levels, serum triglycerides, total cholesterol levels, and low high density lipoprotein (HDL) levels. Atypical antipsychotic use may mediate some of these effects. No study examined CRP's association with actual cardiovascular disease (e. g. coronary artery disease) in BD. Conclusions: In BD, CRP is associated with increases in several cardiovascular risk factors, suggesting that systemic inflammation could be a shared driving force for both outcomes of BD and cardiovascular risk. Further longitudinal research is needed in this area to verify causality, including an examination of actual cardiovascular disease. Non-pharmacological and pharmacological treatments with anti-inflammatory effects should also be investigated, particularly in patients with increased CRP, for their potential to reduce cardiovascular risk in BD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Psychiatry

Cultural adaptation of an appropriate tool for mental health among Kanien'keha:ka: a participatory action project based on the Growth and Empowerment Measure

Liliana Gomez Cardona, Kristyn Brown, Taylor Goodleaf, Mary McComber, Rebecca D'Amico, Allyson Phillips, Cyndy Boyer, Codey Martin, Brooke Splicer, Suzy Goodleaf, Darrell Thompson, Melissa Haswell, Arlene Laliberte, Outi Linnaranta

Summary: The study culturally adapted the Growth and Empowerment Measure for the Kanien'keha:ka people of Quebec, using a qualitative, collaborative, and participatory approach. Through focus group meetings and data analysis, socioculturally relevant elements were integrated to create a versatile assessment tool reflecting local well-being factors.

SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY (2022)

Review Biochemistry & Molecular Biology

Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application

Lara E. Murphy, Trehani M. Fonseka, Chad A. Bousman, Daniel J. Mueller

Summary: There are significant individual differences in the therapeutic effectiveness and adverse effects of antidepressant and antipsychotic medications, which can be partially explained by genetic variation. Evidence-based guidelines are available for pharmacogenetic-guided prescribing of these medications, but key barriers such as economic, educational, regulatory, and ethical issues need to be addressed for optimal patient care outcomes.

MOLECULAR PSYCHIATRY (2022)

Review Neurosciences

Melatonergic agents influence the sleep-wake and circadian rhythms in healthy and psychiatric participants: a systematic review and meta-analysis of randomized controlled trials

Eunsoo Moon, Timo Partonen, Serge Beaulieu, Outi Linnaranta

Summary: This systematic review and meta-analysis examines the effects of melatonin supplements and agonists on sleep-wake cycle and melatonin circadian rhythm. It found that these agents can advance the sleep-wake cycle in both healthy participants and patients with psychiatric disorders, indicating their potential value in regulating circadian rhythms.

NEUROPSYCHOPHARMACOLOGY (2022)

Correction Pharmacology & Pharmacy

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels (10.1055/a-1625-6388)

Jose de Leon, Georgios Schoretsanitis, Robert L. Smith, Espen Molden, Anssi Solismaa, Niko Seppala, Miloslav Kopecek, Patrik Svancer, Ismael Olmos, Carina Ricciardi, Celso Iglesias-Garcia, Ana Iglesias-Alonso, Edoardo Spina, Can-Jun Ruan, Chuan-Yue Wang, Gang Wang, Yi-Lang Tang, Shih-Ku Lin, Hsien-Yuan Lane, Yong Sik Kim, Se Hyun Kim, Anto P. Rajkumar, Dinora F. Gonzalez-Esquivel, Helgi Jung-Cook, Trino Baptista, Christopher Rohde, Jimmi Nielsen, Helene Verdoux, Clelia Quiles, Emilio J. Sanz, Carlos De las Cuevas, Dan Cohen, Peter F. J. Schulte, Aygun Ertugrul, Nitin Chopra, Betsy McCollum, Charles Shelton, Robert O. Cotes, Arun R. Kaithi, John M. Kane, Saeed Farooq, Chee H. Ng, John Bilbily, Christoph Hiemke, Carlos Lopez-Jaramillo, Ian McGrane, Fernando Lana, Chin B. Eap, Manuel Arrojo-Romero, Erich Seifritz, Susanna Every-Palmer, Chad A. Bousman, Emmanuel Bebawi, Rahul Bhattacharya, Deanna L. Kelly, Yuji Otsuka, Judit Lazary, Rafael Torres, Agustin Yecora, Mariano Motuca, Sherry K. W. Chan, Monica Zolezzi, Sami Ouanes, Domenico De Berardis, Sandeep Grover, Ric M. Procyshyn, Richard A. Adebayo, Oleg O. Kirilochev, Andrey Soloviev, Konstantinos N. Fountoulakis, Alina Wilkowska, Muhammad Ayub, Alzira Silva, Raphael M. Bonelli, Jose M. Villagran-Moreno, Benedicto Crespo-Facorro, Henk Temmingh, Eric Decloedt, Maria R. Pedro, Hiroyoshi Takeuchi, Masaru Tsukahara, Gerhard Gruender, Marina Sagud, Andreja Celofiga, Dragana Ignjatovic Ristic, Bruno B. Ortiz, Helio Elkis, Antonio J. Pacheco Palha, Adrian LLerena, Emilio Fernandez-Egea, Dan Siskind, Abraham Weizman, Rim Masmoudi, Shamin Mohd Saffian, Jonathan G. Leung, Peter F. Buckley, Stephen R. Marder, Leslie Citrome, Oliver Freudenreich, Christoph U. Correll, Daniel J. Muller, A. Elif Anil Yagcioglu, Flavian S. Radulescu, Wieslaw J. Cubala

PHARMACOPSYCHIATRY (2022)

Review Pharmacology & Pharmacy

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

Jose de Leon, Georgios Schoretsanitis, Robert L. Smith, Espen Molden, Anssi Solismaa, Niko Seppala, Miloslav Kopecek, Patrik Svancer, Ismael Olmos, Carina Ricciardi, Celso Iglesias-Garcia, Ana Iglesias-Alonso, Edoardo Spina, Can-Jun Ruan, Chuan-Yue Wang, Gang Wang, Yi-Lang Tang, Shih-Ku Lin, Hsien-Yuan Lane, Yong Sik Kim, Se Hyun Kim, Anto P. Rajkumar, Dinora F. Gonzalez-Esquivel, Helgi Jung-Cook, Trino Baptista, Christopher Rohde, Jimmi Nielsen, Helene Verdoux, Clelia Quiles, Emilio J. Sanz, Carlos De las Cuevas, Dan Cohen, Peter F. J. Schulte, Aygun Ertugrul, Nitin Chopra, Betsy McCollum, Charles Shelton, Robert O. Cotes, Arun R. Kaithi, John M. Kane, Saeed Farooq, Chee H. Ng, John Bilbily, Christoph Hiemke, Carlos Lopez-Jaramillo, Ian McGrane, Fernando Lana, Chin B. Eap, Manuel Arrojo-Romero, Erich Seifritz, Susanna Every-Palmer, Chad A. Bousman, Emmanuel Bebawi, Rahul Bhattacharya, Deanna L. Kelly, Yuji Otsuka, Judit Lazary, Rafael Torres, Agustin Yecora, Mariano Motuca, Sherry K. W. Chan, Monica Zolezzi, Sami Ouanes, Domenico De Berardis, Sandeep Grover, Ric M. Procyshyn, Richard A. Adebayo, Oleg O. Kirilochev, Andrey Soloviev, Konstantinos N. Fountoulakis, Alina Wilkowska, Muhammad Ayub, Alzira Silva, Raphael M. Bonelli, Jose M. Villagran-Moreno, Benedicto Crespo-Facorro, Henk Temmingh, Eric Decloedt, Maria R. Pedro, Hiroyoshi Takeuchi, Masaru Tsukahara, Gerhard Gruender, Marina Sagud, Andreja Celofiga, Dragana Ignjatovic Ristic, Bruno B. Ortiz, Helio Elkis, Antonio J. Pacheco Palha, Adrian LLerena, Emilio Fernandez-Egea, Dan Siskind, Abraham Weizman, Rim Masmoudi, Shamin Mohd Saffian, Jonathan G. Leung, Peter F. Buckley, Stephen R. Marder, Leslie Citrome, Oliver Freudenreich, Christoph U. Correll, Daniel J. Muller, A. Elif Anil Yagcioglu, Flavian S. Radulescu, Wieslaw J. Cubala

Summary: This international guideline suggests improving clozapine package inserts globally by utilizing ancestry-based dosing and gradual titration to prevent potential toxicity and ADRs. It defines six personalized titration schedules for different populations and recommends monitoring inflammation globally.

PHARMACOPSYCHIATRY (2022)

Article Psychiatry

Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders

Anthony L. Vaccarino, Derek Beaton, Sandra E. Black, Pierre Blier, Farnak Farzan, Elizabeth Finger, Jane A. Foster, Morris Freedman, Benicio N. Frey, Susan Gilbert Evans, Keith Ho, Mojib Javadi, Sidney H. Kennedy, Raymond W. Lam, Anthony E. Lang, Bianca Lasalandra, Sara Latour, Mario Masellis, Roumen V. Milev, Daniel J. Mueller, Douglas P. Munoz, Sagar V. Parikh, Franca Placenza, Susan Rotzinger, Claudio N. Soares, Alana Sparks, Stephen C. Strother, Richard H. Swartz, Brian Tan, Maria Carmela Tartaglia, Valerie H. Taylor, Elizabeth Theriault, Gustavo Turecki, Rudolf Uher, Lorne Zinman, Kenneth R. Evans

Summary: Brain-CODE is an informatics platform that collects, stores, and integrates data to understand the causes of brain dysfunction and develop new treatment approaches. By providing access to diverse datasets, including clinical, neuroimaging, and molecular data, Brain-CODE facilitates analyses within and across brain disorders. The establishment of Common Data Elements ensures consistency in data collection and enhances the ability to analyze pooled participant-level data.

FRONTIERS IN PSYCHIATRY (2022)

Article Neurosciences

Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study

Prabhjot Dhami, Lena C. Quilty, Benjamin Schwartzmann, Rudolf Uher, Timothy A. Allen, Stefan Kloiber, Raymond W. Lam, Glenda MacQueen, Benicio N. Frey, Roumen Milev, Daniel J. Mueller, Stephen C. Strother, Pierre Blier, Claudio N. Soares, Sagar V. Parikh, Gustavo Turecki, Jane A. Foster, Susan Rotzinger, Sidney H. Kennedy, Faranak Farzan

Summary: The neurobiological correlates of response inhibition can predict the response of patients with major depressive disorder (MDD) to pharmacological and cognitive behavioral therapy treatment. The integrity of response inhibition may be crucial for the success of treatment for MDD. Electrophysiological correlates of response inhibition may serve as a general prognostic marker for treatment response in MDD.

BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING (2023)

Review Biochemistry & Molecular Biology

The Gut Microbiome in Depression and Potential Benefit of Prebiotics, Probiotics and Synbiotics: A Systematic Review of Clinical Trials and Observational Studies

Sauliha R. Alli, Ilona Gorbovskaya, Jonathan C. W. Liu, Nathan J. Kolla, Lisa Brown, Daniel J. Muller

Summary: A growing body of research indicates differences in the gut microbiome of major depressive disorder (MDD) patients compared to healthy controls. Prebiotic, probiotic, and synbiotic treatments show modest benefit in reducing depressive symptoms. However, further studies are needed before these therapies can be implemented in clinical practice.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Biochemistry & Molecular Biology

Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment

Masataka Wada, Yoshihiro Noda, Yusuke Iwata, Sakiko Tsugawa, Kazunari Yoshida, Hideaki Tani, Yoji Hirano, Shinsuke Koike, Daiki Sasabayashi, Haruyuki Katayama, Eric Plitman, Kazutaka Ohi, Fumihiko Ueno, Fernando Caravaggio, Teruki Koizumi, Philip Gerretsen, Takefumi Suzuki, Hiroyuki Uchida, Daniel J. Muller, Masaru Mimura, Gary Remington, Anthony A. Grace, Ariel Graff-Guerrero, Shinichiro Nakajima

Summary: This review discusses potential treatments for treatment-resistant schizophrenia, focusing on the therapeutic potential of neuromodulation. It also proposes a multivariate analysis approach that integrates various pathophysiological perspectives, providing a roadmap for future research in this area.

MOLECULAR PSYCHIATRY (2022)

Correction Psychiatry

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial (vol 12, 101, 2022)

Arun K. Tiwari, Clement C. Zai, C. Anthony Altar, Julie-Anne Tanner, Paige E. Davies, Paul Traxler, James Li, Elizabeth S. Cogan, Matthew T. Kucera, Ana Gugila, Nicole Braganza, Heather Emmerson, Gwyneth Zai, Daniel J. Muller, Robert Levitan, Stefan Kloiber, Zafiris J. Daskalakis, Benicio N. Frey, James M. Bowen, Jean-Eric Tarride, Richard Tytus, Ranjith Chandrasena, Nicholas Voudouris, Valerie H. Taylor, Raymond Tempier, Verinder Sharma, Akshya Vasudev, Peter Dzongowski, Lew Pliamm, Todd Greenspoon, Bryan M. Dechairo, James L. Kennedy

TRANSLATIONAL PSYCHIATRY (2022)

Article Psychiatry

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial

Arun K. Tiwari, Clement C. Zai, C. Anthony Altar, Julie-Anne Tanner, Paige E. Davies, Paul Traxler, James Li, Elizabeth S. Cogan, Matthew T. Kucera, Ana Gugila, Nicole Braganza, Heather Emmerson, Gwyneth Zai, Daniel J. Muller, Robert Levitan, Stefan Kloiber, Zafiris J. Daskalakis, Benicio N. Frey, James M. Bowen, Jean-Eric Tarride, Richard Tytus, Ranjith Chandrasena, Nicholas Voudouris, Valerie H. Taylor, Raymond Tempier, Verinder Sharma, Akshya Vasudev, Peter Dzongowski, Lew Pliamm, Todd Greenspoon, Bryan M. Dechairo, James L. Kennedy

Summary: The pharmacological treatment of depression involves trial and error, with a low remission rate during the first medication trial. However, a study showed that patients who received treatment guided by combinatorial pharmacogenomic testing had significant improvements in response and remission rates.

TRANSLATIONAL PSYCHIATRY (2022)

Article Behavioral Sciences

Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy

Caroline W. Espinola, Yuelee Khoo, Roohie Parmar, Ilya Demchenko, Benicio N. Frey, Roumen Milev, Arun Ravindran, Sagar Parikh, Keith Ho, Susan Rotzinger, Wendy Lou, Raymond W. Lam, Sidney H. Kennedy, Venkat Bhat

Summary: This study aimed to report the frequency and severity of side effects in patients with major depressive disorder (MDD) receiving adjunctive therapy of escitalopram and aripiprazole, and to examine the association between pretreatment anxious depression and the number and presence of specific side effects. The results demonstrated that the most frequent and severe side effects were related to the central nervous system. Furthermore, patients with anxious depression were more likely to experience side effects, especially those related to anxiety, when receiving escitalopram treatment.

BRAIN AND BEHAVIOR (2022)

Article Psychology, Clinical

Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 report

Mehri Sajjadian, Rudolf Uher, Keith Ho, Stefanie Hassel, Roumen Milev, Benicio N. Frey, Faranak Farzan, Pierre Blier, Jane A. Foster, Sagar Parikh, Daniel J. Mueller, Susan Rotzinger, Claudio N. Soares, Gustavo Turecki, Valerie H. Taylor, Raymond W. Lam, Stephen C. Strother, Sidney H. Kennedy

Summary: Predicting treatment outcomes for major depressive disorder can be improved by combining clinical, neuroimaging, and molecular data. Early measurement during treatment can increase precision, but adding more features does not necessarily enhance prediction accuracy.

PSYCHOLOGICAL MEDICINE (2023)

Article Health Care Sciences & Services

A Virtual Reality-Assisted Cognitive Behavioral Therapy for and With Inuit in Quebec: Protocol for a Proof-of-Concept Randomized Controlled Trial

Quinta Seon, Noor Mady, Michelle Yang, Maharshee Karia, Myrna Lashley, Claudia Sescu, Maud Lalonde, Stephen Puskas, Joy Outerbridge, Echo Parent-Racine, Catherine Pagiatakis, Liliana Gomez-Cardona, Di Jiang, Stephane Bouchard, Outi Linnaranta

Summary: This study presents a protocol for a culturally adapted virtual reality cognitive behavioral therapy trial among Inuit in Quebec. The research aims to investigate the feasibility, benefits, and challenges of the culturally adapted intervention compared to a commercial self-management program, as well as examine self-rated mental well-being and objective psychophysiological measures. The study's importance lies in meeting the need for accessible and appropriate psychological well-being resources for Inuit, incorporating novel technology and measurement methods, and providing evidence for culturally adapted RCTs.

JMIR RESEARCH PROTOCOLS (2023)

Review Psychiatry

Safe and valid? A systematic review of the psychometric properties of culturally adapted depression scales for use among Indigenous populations

Michelle Yang, Quinta Seon, Liliana Gomez Cardona, Maharshee Karia, Gajanan Velupillai, Valerie Noel, Outi Linnaranta

Summary: Implementing culturally sensitive psychometric measures of depression can improve acceptance and reliability. However, the psychometric properties of culturally adapted depression scales remain unclear, with some improvements in cultural sensitivity but potential decreases in specificity and negative predictive value.

CAMBRIDGE PRISMS-GLOBAL MENTAL HEALTH (2023)

Article Clinical Neurology

Associations of maternal prenatal psychological symptoms and saliva cortisol with neonatal meconium microbiota: A cross-sectional study

Nadia Deflorin, Ulrike Ehlert, Rita T. Amiel Castro

Summary: Changes in the gut microbiome of infants have been associated with maternal psychological symptoms during pregnancy. This study found that maternal prenatal depressive symptoms are associated with lower diversity of the infant's microbiome, while maternal saliva cortisol levels are linked to increased diversity and changes in specific bacterial groups. Further research is needed to understand the implications of these microbiota alterations for child health.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

Association between suicidal behavior and impaired glucose metabolism in first-episode drug-naive patients with schizophrenia

Zheng Ma, Hui-Xia Zhou, Da-Chun Chen, Dong-Mei Wang, Xiang-Yang Zhang

Summary: The impaired glucose metabolism in drug-na & iuml;ve schizophrenia patients is strongly associated with suicidal behavior, suggesting that glucose metabolism abnormalities may be potential biomarkers of suicide in schizophrenia patients. Regular monitoring of glucose metabolism variables is essential for suicide prevention.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

Transdiagnostic cognitive biases in psychiatric disorders: A systematic review and network meta-analysis

Katie M. Lavigne, Jiaxuan Deng, Delphine Raucher-Chene, Adele Hotte-Meunier, Chloe Voyer, Lisa Sarraf, Martin Lepage, Genevieve Sauve

Summary: Psychiatric disorders are characterized by cognitive deficits and cognitive biases, which are associated with specific symptoms. While cognitive biases are present across diagnoses, their severity varies.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

Gamma oscillations in the mPFC: A potential predictive biomarker of depression and antidepressant effects

Yong-Yu Yin, Jiao-Zhao Yan, Shi-Xin Lai, Qian-Qian Wei, Si-Rui Sun, Li-Ming Zhang, Yun-Feng Li

Summary: This study found that gamma oscillations are closely associated with depression and may serve as predictive biomarkers of depression. Chronic restraint stress and lipopolysaccharide induced significant depression-like behaviors in mice and reduced gamma oscillations in the medial prefrontal cortex. Administration of ketamine, scopolamine, or fluoxetine increased gamma oscillations and exhibited rapid-acting antidepressant effects.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

Transcriptomic analyses of rats exposed to chronic mild stress: Modulation by chronic treatment with the antipsychotic drug lurasidone

Veronica Begni, Moira Marizzoni, Kerstin Camile Creutzberg, Diana Morena Silipo, Mariusz Papp, Annamaria Cattaneo, Marco Andrea Riva

Summary: Exposure to stressful experiences is a significant risk factor for mental disorders, and pharmacological interventions targeting stress-induced alterations can help restore brain function. Lurasidone, an antipsychotic drug, has been shown to normalize the impairments caused by stress exposure and could be a valuable treatment for stress-induced mental illnesses. However, the mechanisms underlying the therapeutic effects of lurasidone are not well understood. This study found that chronic lurasidone treatment counteracted some of the transcriptional changes induced by chronic mild stress exposure, providing new insights into the potential therapeutic effects of lurasidone.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

Early life interpersonal stress and depression: Social reward processing as a potential mediator

Esther E. Palacios-Barrios, Kunal Patel, Jamie L. Hanson

Summary: This review examines the association between early life interpersonal stress (ELIS) and depression, as well as the underlying mechanisms. The research shows that ELIS affects how youth respond to social rewards, and similar impairments in social reward processing are observed in youth with depression. The authors propose a preliminary model that suggests neurobehavioral disruptions in social reward processing as a mediating factor in the connection between ELIS and depression.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

Metabolomics and transcriptomics analysis of prefrontal cortex in the Pax2 neuron-specific deletion mice

Rui Li, Jiaming Tang, Yizhuo Wang, Ying Wang, Hua Yang, Hongen Wei

Summary: Restricted and repetitive behaviors (RRBs) are characteristic features of neuropsychiatric disorders. This study focused on repetitive self-grooming behavior and investigated the involvement of the Pax2 gene in its control. Through the use of Pax2 neuron-specific deletion mice, the study found that the deletion of Pax2 gene affects the expression of the Arc gene in the prefrontal cortex, leading to impaired synaptic plasticity and excitatory/inhibitory imbalance, thereby contributing to the occurrence of repetitive self-grooming behavior.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response

Sara Derosa, Paulina Misztak, Jessica Mingardi, Giulia Mazzini, Heidi Kaastrup Muller, Laura Musazzi

Summary: This study investigated the involvement of neurotrophic signaling pathways in stress vulnerability/resilience and fast antidepressant response/non-response to ketamine in a rat model of depression. The findings showed that stress and ketamine induced specific changes in these pathways in different brain areas and subcellular fractions.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Review Clinical Neurology

To what extent does white matter map to cognition in bipolar disorder? A systematic review of the evidence

Georgia F. Caruana, Sean P. Carruthers, Michael Berk, Susan L. Rossell, Tamsyn E. Van Rheenen

Summary: Cognitive impairment is related to both white matter macrostructure and microstructure in bipolar disorder patients. However, there is inconsistency in the results of the studies examining this relationship. Some studies have found an association between higher fractional anisotropy in white matter and better complex attention skills and executive functioning in bipolar disorder patients, while others have found no associations. Further research with increased statistical power and standardized methods is needed.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Review Clinical Neurology

Effectiveness of rTMS and tDCS treatment for chronic TBI symptoms: A systematic review and meta-analysis

Alberto Galimberti, Martin Tik, Giovanni Pellegrino, Anna-Lisa Schuler

Summary: This study provides a systematic review and meta-analysis on the effectiveness of repetitive transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) for post-traumatic brain injury (TBI) symptoms. The results show that non-invasive brain stimulation techniques have a small overall effect on TBI sequelae, with significant effects observed for anxiety and headache. However, larger randomized controlled trials with longer follow-ups, optimized stimulation parameters, and standardized methodology are needed to establish the efficacy of these techniques in addressing TBI sequelae.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

Doxycycline diminishes the rewarding and psychomotor effects induced by morphine and cocaine

Amanda J. Sales, Pedro H. Gobira, Joa F. C. Pedrazzi, Joao R. Silveia, Elaine Del Bel, Felipe V. Gomes, Francisco S. Guimaraes

Summary: The study found that doxycycline can inhibit metalloproteinase in the brain and attenuate the rewarding effects and locomotor sensitization of drug abuse. This suggests that doxycycline could be repurposed for the treatment of substance use disorders.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

An updated overview on the relationship between human gut microbiome dysbiosis and psychiatric and psychological disorders

Alejandro Borrego-Ruiz, Juan J. Borrego

Summary: There is substantial evidence that the development of the nervous system is related to the composition and functions of the gut microbiome. The communication between the central nervous system (CNS) and the gut microbiota is bidirectional, with various routes such as immune, endocrine, and neural circuits. Dysbiosis of the gut microbiota has been associated with neuropsychiatric diseases and psychological disorders. Fecal microbiota transplantation (FMT) therapy has shown a causal-effect relationship between the gut microbiota and behavioral features. Interventions based on prebiotics, probiotics, or synbiotics have demonstrated their influence on neurological disorders through the synthesis of neuroactive compounds and regulation of inflammatory and endocrine processes. Further research is needed to explore the impact of gut microbiota dysbiosis on psychiatric and psychological disorders and the potential therapeutic role of microbiota-based interventions.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

Associations of resilience, white matter topological organization, and cognitive functions in first-episode, drug-naive schizophrenia patients: A moderated mediation analysis

Zhinan Li, Zhuang Kang, Xiaowei Xia, Leijun Li, Junyan Wu, Jiamin Dai, Tong Liu, Cai Chen, Yong Qiu, Ming Chen, Yanxi Liu, Ziyi Zhang, Zili Han, Zhengjia Dai, Qinling Wei

Summary: This study found that patients with schizophrenia showed lower levels of resilience and cognitive functions compared to healthy controls, as well as abnormal global properties and nodal metrics in brain networks. Furthermore, characteristic path length might moderate the relationship between resilience and working memory in these patients.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

Executive functioning trajectories and their prospective association with inflammatory biomarkers in schizophrenia and non-psychiatric comparison participants

David H. Adamowicz, Tsung-Chin Wu, Rebecca Daly, Michael R. Irwin, Dilip Jeste, Xin M. Tu, Lisa T. Eyler, Ellen E. Lee

Summary: This study aimed to explore the relationship between executive functioning and inflammatory biomarkers in people with schizophrenia. The results showed that systemic inflammation did not predict long-term declines in executive functioning. This suggests the need for further research to better understand the relationship and mechanisms between inflammation and cognition in schizophrenia.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)

Article Clinical Neurology

A multivariate cognitive approach to predict social functioning in recent onset psychosis in response to computerized cognitive training

Nina Walter, Julian Wenzel, Shalaila S. Haas, Letizia Squarcina, Carolina Bonivento, Anne Ruef, Dominic Dwyer, Theresa Lichtenstein, Oeznur Bastruek, Alexandra Stainton, Linda A. Antonucci, Paolo Brambilla, Stephen J. Wood, Rachel Upthegrove, Stefan Borgwardt, Rebekka Lencer, Eva Meisenzahl, Raimo K. R. Salokangas, Christos Pantelis, Alessandro Bertolino, Nikolaos Koutsouleris, Joseph Kambeitz, Lana Kambeitz-Ilankovic

Summary: Clinical and neuroimaging data can be used to predict the potential of cognitive training to improve social functioning in recent onset psychosis patients. The use of multivariate pattern analysis and support vector machine classifier allows for the prediction of social functioning improvement based on baseline cognitive data. The findings suggest that cognitive data can provide a robust individual estimate of future social functioning for patients with recent onset psychosis.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2024)